These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37428078)

  • 21. Ifenprodil effects on GluN2B-containing glutamate receptors.
    Amico-Ruvio SA; Paganelli MA; Myers JM; Popescu GK
    Mol Pharmacol; 2012 Dec; 82(6):1074-81. PubMed ID: 22936815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, Pharmacological Evaluation and Docking Studies of GluN2B-Selective NMDA Receptor Antagonists with a Benzo[7]annulen-7-amine Scaffold.
    Gawaskar S; Temme L; Schreiber JA; Schepmann D; Bonifazi A; Robaa D; Sippl W; Strutz-Seebohm N; Seebohm G; Wünsch B
    ChemMedChem; 2017 Aug; 12(15):1212-1222. PubMed ID: 28749574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds.
    Temme L; Bechthold E; Schreiber JA; Gawaskar S; Schepmann D; Robaa D; Sippl W; Seebohm G; Wünsch B
    Eur J Med Chem; 2020 Mar; 190():112138. PubMed ID: 32070917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.
    Burger PB; Yuan H; Karakas E; Geballe M; Furukawa H; Liotta DC; Snyder JP; Traynelis SF
    Mol Pharmacol; 2012 Aug; 82(2):344-59. PubMed ID: 22596351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug.
    Mazumder MK; Borah A
    Med Hypotheses; 2014 Dec; 83(6):740-6. PubMed ID: 25459147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Methyl-D-Aspartate (NMDA) Receptor Antagonists and their Pharmacological Implication: A Medicinal Chemistry-oriented Perspective Outline.
    Rana V; Ghosh S; Bhatt A; Bisht D; Joshi G; Purohit P
    Curr Med Chem; 2024; 31(29):4725-4744. PubMed ID: 38638036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and in vitro characterisation of ifenprodil-based fluorescein conjugates as GluN1/GluN2B N-Methyl-D-aspartate receptor antagonists.
    Dhilly M; Becerril-Ortega J; Colloc'h N; MacKenzie ET; Barré L; Buisson A; Nicole O; Perrio C
    Chembiochem; 2013 Apr; 14(6):759-69. PubMed ID: 23532918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico design based on quantum chemical, molecular docking studies and ADMET predictions of ciprofloxacin derivatives as novel potential antibacterial and antimycrobacterium agents.
    Benselama W; Benchouk W
    J Biomol Struct Dyn; 2024 Sep; 42(15):7650-7666. PubMed ID: 37551116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation.
    Temme L; Frehland B; Schepmann D; Robaa D; Sippl W; Wünsch B
    Eur J Med Chem; 2018 Jan; 144():672-681. PubMed ID: 29289890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists derived from 3-benzazepines: synthesis and pharmacological evaluation of benzo[7]annulen-7-amines.
    Benner A; Bonifazi A; Shirataki C; Temme L; Schepmann D; Quaglia W; Shoji O; Watanabe Y; Daniliuc C; Wünsch B
    ChemMedChem; 2014 Apr; 9(4):741-51. PubMed ID: 24677663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists.
    Liu W; Jiang X; Zu Y; Yang Y; Liu Y; Sun X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2020 Aug; 200():112447. PubMed ID: 32450321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based discovery of antagonists for GluN3-containing N-methyl-D-aspartate receptors.
    Kvist T; Greenwood JR; Hansen KB; Traynelis SF; Bräuner-Osborne H
    Neuropharmacology; 2013 Dec; 75():324-36. PubMed ID: 23973313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and
    Konecny J; Misiachna A; Hrabinova M; Pulkrabkova L; Benkova M; Prchal L; Kucera T; Kobrlova T; Finger V; Kolcheva M; Kortus S; Jun D; Valko M; Horak M; Soukup O; Korabecny J
    Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33375115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Synthesis, and Biological Evaluation of
    Lin G; Xu Q; Li J; Chu Z; Ma X; Zhu Q; Zhao Y; Mo J; Ye W; Shao L; Fang T; He M; Yue S; Dai M
    J Med Chem; 2024 Mar; 67(5):3358-3384. PubMed ID: 38413367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synaptic NMDA receptors in basolateral amygdala principal neurons are triheteromeric proteins: physiological role of GluN2B subunits.
    Delaney AJ; Sedlak PL; Autuori E; Power JM; Sah P
    J Neurophysiol; 2013 Mar; 109(5):1391-402. PubMed ID: 23221411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting NMDA receptor in Alzheimer's disease: identifying novel inhibitors using computational approaches.
    Siddiqui AJ; Badraoui R; Jahan S; Alshahrani MM; Siddiqui MA; Khan A; Adnan M
    Front Pharmacol; 2023; 14():1208968. PubMed ID: 37416066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders.
    Egunlusi AO; Joubert J
    Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
    Fernandes A; Wojcik T; Baireddy P; Pieschl R; Newton A; Tian Y; Hong Y; Bristow L; Li YW
    Eur J Pharmacol; 2015 Nov; 766():1-8. PubMed ID: 26325093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-Based Virtual Screening to Identify Negative Allosteric Modulators of NMDA.
    Sherwani ZA; Khalil R; Nur-E-Alam M; Ahmed S; Ul-Haq Z
    Med Chem; 2022; 18(9):990-1000. PubMed ID: 35249502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands.
    Thum S; Schepmann D; Kalinin DV; Ametamey SM; Wünsch B
    ChemMedChem; 2018 Dec; 13(23):2522-2529. PubMed ID: 30312542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.